Project Grant R01CA292464
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$600K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $697,763 to The University of Texas MD Anderson Cancer Center to investigate the genetic determinants that allow the bacterium Fusobacterium nucleatum (F. nucleatum) to selectively colonize colorectal cancer (CRC) tumors. The research aims to elucidate the mechanisms by which F. nucleatum, a member of the oral microbiome, is able to persist within the CRC tumor microenvironment...
The National Cancer Institute (NCI) awarded a five-year, $626,893 Project Grant (CFDA 93.396 - Cancer Biology Research) to The University of Texas MD Anderson Cancer Center to investigate the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity and cancer progression. The project aims to functionally map the cellular and metabolic features of these bacterial-colonized microniches in patient tumor tissues, delineate the human cell types harboring...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $253,405 to support research and training activities at Columbia University's Health Sciences Division aimed at improving bacterial cancer therapeutics. The project seeks to identify key pathways that allow E. coli bacteria to selectively migrate to and colonize tumor tissues, which could lead to more effective cancer treatment approaches using bacteria as delivery vehicles....
This $1,384,482 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate the role of bacterial DNA methyltransferases in cancer pathoadaptation and their potential as therapeutic targets.
The research, led by the University of Texas MD Anderson Cancer Center, aims to determine if the DNA methyltransferase (M.FNI) from the colorectal cancer-associated bacterium Fusobacterium nucleatum contributes to its virulence...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to develop an intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The $627,422 award to the Regents of the University of Michigan will fund research to engineer E. coli bacteria to display an enzyme that neutralizes the carcinogenic colibactin toxin. The project will optimize the surface display of this anti-toxin...
This $560,297 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the Icahn School of Medicine at Mount Sinai to functionally and molecularly characterize "oncofetal stem cells" in colorectal cancer (CRC). The key objectives are to: 1) generate reporters to track the dynamics of CRC stem cell populations, 2) determine the molecular drivers of the oncofetal stem cell state and tumor plasticity, and 3) identify...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $193,144 to The Trustees of Columbia University in the City of New York to support a multidisciplinary postdoctoral training program focused on gastrointestinal (GI) cancers. The program aims to advance the understanding of GI cancers and reduce their morbidity and mortality by training the next generation of diverse GI cancer researchers. The 5-year award will support a...
The federal Project Grant award of $221,456 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will enable the development and optimization of a novel approach to enrich microbes from clinical cancer samples for deep metaproteomic analysis. The award, effective April 1, 2025 through March 31, 2028, will be utilized by the Regents of the University of Minnesota to develop a Bio-Orthogonal Non-Canonical Amino Acid Tagging (BONCAT) method coupled...
This federal Project Grant award for $281,606, provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), will fund research conducted by Dr. Rabi Upadhyay at New York University (NYU) School of Medicine to investigate how specific gut bacteria can drive anti-tumor immunity in lung cancer. The research aims to elucidate the mechanisms by which gut colonization with certain Bacteroides commensals can lead to systemic anti-tumor effects, even in the absence of...
This Project Grant award of $400,890, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The research team at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will utilize...